To investigate the prevention of OM-85 on bronchiectasis exacerbations (iPROBE) in Chinese patients: Study protocol for a randomized controlled trial

Trials

Volumn 15, Issue 1, 2014, Pages

  Gao, Jinming ^a   Gao, Xiang ^b,c   Kong, Lingfei ^d  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Bronchiectasis; OM 85; Placebo; Pulmonary exacerbation

Indexed keywords

IMMUNOSTIMULATING AGENT; OM 85; PLACEBO; UNCLASSIFIED DRUG; BRONCHO-VAXOM; CELL EXTRACT; IMMUNOLOGIC FACTOR; MICROCAPSULE;

ARTICLE; BRONCHIECTASIS; CHINESE; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PREVENTION STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE COURSE; DRUG ADMINISTRATION; EPIDEMIOLOGY; ETHNOLOGY; IMMUNOLOGY; METHODOLOGY; MICROCAPSULE; ORAL DRUG ADMINISTRATION; TIME;

ADMINISTRATION, ORAL; ASIAN CONTINENTAL ANCESTRY GROUP; BRONCHIECTASIS; CAPSULES; CELL EXTRACTS; CHINA; CLINICAL PROTOCOLS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOLOGIC FACTORS; PROSPECTIVE STUDIES; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84899953459     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-15-150     Document Type: Article

References (23)

1. Karadag B, Karakoc F, Ersu R, Kut A, Bakac S, Dagli E. Non-cystic-fibrosis bronchiectasis in children: a persisting problem in developing countries. Respiration 2005, 72(3):233-238. 10.1159/000085362, 15942290.
2. O'Donnell AE. Bronchiectasis. Chest 2008, 134(4):815-823. 10.1378/chest.08-0776, 18842914.
3. Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010, 65:577. 10.1136/thx.2010.142778, 20627912.
4. De Soyza A, Brown JS, Loebinger MR. Research priorities in bronchiectasis. Thorax 2013, 68:695-696. 10.1136/thoraxjnl-2012-202893, 23242949.
5. Seitz AE, Olivier KN, Adjemian J, Holland SM, Prevots R. Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. Chest 2012, 142(2):432-439. 3425339, 22302301.
6. Whitters D, Stockley R. Immunity and bacterial colonisation in bronchiectasis. Thorax 2011, 67(11):1006-1013.
7. Chalmers JD, Hill AT. Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. Mol Immunol 2013, 55(1):27-34. 10.1016/j.molimm.2012.09.011, 23088941.
8. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics - part 2: advantages and disadvantages of long-term, low-dose macrolide therapy. Respiration 2011, 81(1):75-87. 10.1159/000320320, 20733282.
9. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, Milne D, Fergusson W, Tuffery C, Sexton P, Storey L, Ashton T. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012, 380(9842):660-667. 10.1016/S0140-6736(12)60953-2, 22901887.
10. Fennelly KP, Griffith DE. Azithromycin in non-cystic-fibrosis bronchiectasis. Lancet 2013, 381(9860):27.
11. Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012, 186(7):657-665. 10.1164/rccm.201203-0487OC, 22744718.
12. Anthonisen NR. OM-8BV for COPD. Am J Respir Crit Care Med 1997, 156(6):1713-1714. 10.1164/ajrccm.156.6.ed15-97, 9412544.
13. Collet JP, Shapiro P, Ernst P, Renzi T, Ducruet T, Robinson A, The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997, 156(6):1719-1724. 10.1164/ajrccm.156.6.9612096, 9412546, The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant.
14. Soler M, Mutterlein R, Cozma G. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration 2007, 74(1):26-32. 10.1159/000093933, 16772707.
15. Mackley R. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis. Thorax 2013, 68:866.
16. O'Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998, 113(5):1329-1334. 10.1378/chest.113.5.1329, 9596315.
17. Little RJ, D'Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, Frangakis C, Hogan JW, Molenberghs G, Murphy SA, Neaton JD, Rotnitzky A, Scharfstein D, Shih WJ, Siegel JP, Stern H. The prevention and treatment of missing data in clinical trials. N Engl J Med 2012, 367(14):1355-1360. 10.1056/NEJMsr1203730, 3771340, 23034025.
18. Martinez-Garcia MA, Soler-Cataluna JJ, Donat Sanz Y, Catalan Serra P, Agramunt Lerma M, Ballestin Vicente J, Perpina-Tordera M. Factors associated with bronchiectasis in patients with COPD. Chest 2011, 140(5):1130-1137. 10.1378/chest.10-1758, 21546440.
19. Chang AB, Grimwood K, Robertson CF, Wilson AC, van Asperen PP, O'Grady KA, Sloots TP, Torzillo PJ, Bailey EJ, McCallum GB, Masters IB, Byrnes CA, Chatfield MD, Buntain HM, Mackay IM, Morris PS. Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial. Trials 2012, 13:156. 10.1186/1745-6215-13-156, 3488323, 22937736.
20. Nick JA, Moskowitz SM, Chmiel JF, Forssen AV, Kim SH, Saavedra MT, Saiman L, Taylor-Cousar JL, Nichols DP. Azithromycin May Antagonize Inhaled Tobramycin when Targeting Pseudomonas aeruginosa in Cystic Fibrosis. Ann Am Thorac Soc 2014, 11:342-350.
21. Murray MP, Govan JR, Doherty CJ, Simpson AJ, Wilkinson TS, Chalmers JD, Greening AP, Haslett C, Hill AT. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011, 183(4):491-499. 10.1164/rccm.201005-0756OC, 20870753.
22. Chang AB, Bilton D. Exacerbations in cystic fibrosis: 4-Non-cystic fibrosis bronchiectasis. Thorax 2008, 63(3):269-276. 10.1136/thx.2006.060913, 18308962.
23. Murray MP, Turnbull K, MacQuarrie S, Pentland JL, Hill AT. Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. Eur Respir J 2009, 34(1):125-131. 10.1183/09031936.00160508, 19196812.